Navigation Links
XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
Date:11/17/2011

nd an investigator for XEOMIN®. "Merz has established a positive presence in the movement disorder community and XEOMIN® continues to provide value for patients and doctors."

XEOMIN® is approved in 20 countries for the treatment of blepharospasm, in 21 countries for the treatment of cervical dystonia (also known as spasmodic torticollis), and in 17 countries for post-stroke spasticity of the upper limb. XEOMIN® is not approved for the treatment of spasticity in the U.S.

The results of an additional study evaluating the safety and efficacy of XEOMIN® in the treatment of cervical dystonia when administered at flexible dosing regimens, as well as data showing the safety and efficacy of XEOMIN® in the treatment of UL post-stroke spasticity, will also be presented:

  • Poster 129: Sustained efficacy with incobotulinumtoxinA (XEOMIN®; botulinum neurotoxin type A, free from accessory proteins) for up to 89 weeks in upper limb post-stroke spasticity (Kanovsky, et al.)
  • Poster 131: IncobotulinumtoxinA (XEOMIN®; botulinum neurotoxin type A, free from accessory proteins): Flexibility of dosing and injection intervals in cervical dystonia (Evidente, et al.)

About XEOMIN®

Botulinum toxin type A is naturally produced by Clostridium botulinum as a larger protein complex containing therapeutically unnecessary accessory or complexing proteins.

XEOMIN® (incobotulinumtoxinA) is manufactured using an FDA-approved state-of-the-art biotechnological process, which yields the pure neurotoxin with a low foreign protein content. Foreign proteins are considered as one of the factors for secondary therapy failure.

Since its launch in 2005, more than 261,000 patients have been treated with XEOMIN® worldwide. It is approved in 20 countries for the treatment o
'/>"/>

SOURCE Merz Pharmaceuticals GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
2. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
3. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
6. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
7. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
8. New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI
9. Abbott Statement on the Results of the AIM-HIGH Study Presented at AHA 2011
10. Positive Results from Phase 2 Trial of Mesoblasts Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
11. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014   ... today the appointment of J. Patrick Ravenel ... years of enterprise software and systems experience and a ... Fortune 500 companies. "Patrick has been ... class software and systems and is known industry-wide for ...
(Date:10/1/2014)... , Oct. 1, 2014  SI-BONE, Inc., a medical device ... ® a minimally invasive surgical (MIS) device indicated for ... announced the expansion of its European operations with the formation ... Schaber as General Manager, Germany.  Mr. Schaber will join ... of Europe , Middle East ...
(Date:10/1/2014)... , Switzerland , October 1, 2014 ... in Clinical Genomics and Next Generation Sequencing (NGS) data ... clinicians to run full cystic fibrosis analysis in a ... identification and characterisation of all types of variants in ... Until now, it has not been possible ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... RRY Publications LLC today announced the presenter line-up for ... is slated to bring together the largest gathering of ... New York.  Participants will learn about investment opportunity in ... the growing market potential for the industry.   ...
... Md., Feb. 7, 2011 Today the U.S. Food and ... to conduct postmarket surveillance studies to determine the length of ... pain or other reasons. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... to the temporal bone in the skull. A person may ...
Cached Medicine Technology:6th Annual New York Stem Cell Summit Presenters Announced 2FDA Orders Postmarket Surveillance of Certain TMJ Implants 2FDA Orders Postmarket Surveillance of Certain TMJ Implants 3
(Date:10/1/2014)... ST. LOUIS, MO (PRWEB) October 01, 2014 ... up for Castlewood Eating Disorder Treatment Center’s first ever charity ... provides grants for people with eating disorders who cannot afford ... Fox Run Golf Club in Eureka, Mo. , The ... time at noon. A reception and award dinner will begin ...
(Date:10/1/2014)... Maine (PRWEB) October 01, 2014 Between ... disorders in the U.S., according to figures from the ... Related Diseases Association (AARDA), and many of them have ... chance of having undiagnosed celiac disease. Gluten Free ... raise awareness of undiagnosed celiac disease by publishing a ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 NoteSwift Inc., ... EHR versions 10.0, 12.1 and 13.0. NoteSwift is the ... as commands to navigate and document clinical information at ... provider spends creating a patient note by more than ... of the major pain points providers state impedes EHR ...
(Date:10/1/2014)... IL (PRWEB) October 01, 2014 On ... two Chicago-based finalists in the Martha Stewart American Made ... small businesses across the country in the fields of ... to be recognized as a finalist in the MSAMAs, ... inspiring products that are improving local communities and changing ...
(Date:10/1/2014)... Deland, Florida (PRWEB) October 01, 2014 ... to promote awareness and early detection plans while raising ... to support Breast Cancer Awareness Month in ... Water also wants to promote the importance of having ... contaminated drinking water may be linked to certain forms ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2
... /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: PMD; PREMF.pk) ("PreMD" ... quarter of fiscal 2008 ended,September 30, 2008 ("Q3 2008")., ... the PREVU* appeal is being reviewed by the ... the agreement with AstraZeneca has been terminated; ...
... BPA might lessen chances of successful pregnancy, research suggests ... a controversial chemical used to harden plastic packaging for ... report. , Bisphenol A (BPA) could hurt the chances ... embryos to attach to the uterus, according to presentations ...
... Stem Cell ... Biology Research, ST. ... with AlphaGenix, Inc., a,leading developer and manufacturer of products for basic ... of,AlphaGenix-developed antibodies and research tools for the fields of,regenerative medicine and ...
... socioeconomic factor influencing outcomes, study finds , , THURSDAY, Nov. ... die from inoperable non-small cell lung cancer than women, ... most important factor influencing overall survival of patients with ... of researchers in six U.S. cities studied 1,365 patients ...
... Ga., Nov. 13 On behalf of its 24,965,members ... called for the public release of the details related ... Dougherty County Commission,on changes to the health care plan ... to the county commissioners expressing concerns and,asking questions about ...
... Popular Ribbon Campaign Moves from Bumpers to Blogs , ... San Mateo, ... the Alzheimer,s Association teamed up in the fight against Alzheimer,s, ... media campaign to spread awareness of this growing epidemic. The Purple Ribbon ...
Cached Medicine News:Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 2Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 3Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 4Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 5Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 6Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 7Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 8Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 9Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 10Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 11Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 12Health News:PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer 13Health News:Chemical in Plastics May Cause Fertility Problems 2Health News:Chemical in Plastics May Cause Fertility Problems 3Health News:Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc. 2Health News:Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc. 3Health News:Lung Cancer May Be Deadlier for Men 2Health News:CAGW Questions Healthcare Plan Options Presented to the Dougherty County Commission 2Health News:Caring.com and Alzheimer's Association Use Social Media to Help Spread Awareness for the Nation's Sixth Leading Cause of Death 2Health News:Caring.com and Alzheimer's Association Use Social Media to Help Spread Awareness for the Nation's Sixth Leading Cause of Death 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: